Roth Capital analyst Joseph Pantginis initiates coverage on shares of Sophiris Bio Inc (NASDAQ:SPHS) as the analyst provides a closer look at the …
Sophiris Bio Inc. (NASDAQ:SPHS), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced the pricing of an underwritten public …
Sophiris Bio Inc (NASDAQ:SPHS), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced that it intends to offer and …
Biotech firm Sophiris Bio Inc (NASDAQ:SPHS) just posted second-quarter results as well as an update on its progress for its clinical development program. …
Sophiris Bio Inc (NASDAQ:SPHS), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three and …
Shares of Sophiris Bio Inc (NASDAQ:SPHS) surged by more than 90% today as a result of positive results from its mid-stage trial. The company announced …
Sophiris Bio Inc (NASDAQ:SPHS) shareholders celebrate over 110% gain in the stock this morning, after the drug maker announced positive results from its Phase IIa open-label, …
Healthcare analysts are weighing in on biotech stocks Portola Pharmaceuticals Inc (NASDAQ:PTLA) and Sophiris Bio Inc (NASDAQ:SPHS), as shares of both companies fell sharply …
By Terry Chrisomalis Anavex Life Sciences Corp On November 9, 2015 Anavex Life Sciences Corp. (NASDAQ:AVXL) reported positive phase 2a results for the …
Maxim Group’s healthcare analyst Jason Kolbert weighed in today with research reports on the Canadian urology company Sophiris Bio Inc (NASDAQ:SPHS), Israeli stem cell company Pluristem Therapeutics Inc. (NASDAQ:PSTI), …
